Thalidomide in cancer: Potential uses and limitations

BioDrugs

Volumn 15, Issue 3, 2001, Pages 163-172

  Singhal, S ^a   Mehta, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PYRIDOXINE; THALIDOMIDE;

BRADYCARDIA; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

EID: 0035033777     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115030-00003     Document Type: Review

References (74)

1. Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century
2. Thalidomide and congeners as anti-inflammatory agents
3. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations
4. Immunomodulation by thalidomide and thalidomide analogues
5. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide
6. Thalidomide for the treatment of chronic graft-versus-host disease
7. Thalidomide (N-phthaloyl-glutamide) in the treatment of advanced cancer
8. Clinical experiences with thalidomide in patients with cancer
9. Antitumor activity of thalidomide in refractory multiple myeloma
10. Langerhans-cell histiocytosis in the adult: Regressive parotid involvement following thalidomide therapy
11. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review
12. Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide
13. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide
14. Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies
15. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre
16. Langerhans histiocytosis in adults: Cutaneous and mucous lesion regression after treatment with thalidomide
17. Pharmacokinetics of thalidomide in an elderly prostate cancer population
18. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM)
19. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters
20. Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma
21. Thalidomide is effective in the treatment of recurrent, refractory multiple myeloma (MM)
22. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients
23. Thalidomide in the treatment of relapsed and refractory myeloma
24. Peripheral blood stem cell collection (PBSC) after CAD + G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration
25. Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease
26. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
27. Thalidomide alone or with dexamethasone for multiple myeloma
28. Thalidomide for resistant and relapsing myeloma
29. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders
30. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
31. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas
32. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
33. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
34. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
35. Effect of thalidomide on gastrointestinal toxic effects of irinotecan
36. Activity of thalidomide in AIDS-related Kaposi's sarcoma
37. Phase II evaluation of thalidomide in patients with metastatic breast cancer
38. Encouraging improvement in cytopenias of patients with myelodysplastic syndromes (MDS) with thalidomide
39. BLT-D (biaxin, low-dose thalidomide and dexamethasone) produces consistent responses in myeloma and Waldenstrom's macroglobulinemia
40. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
41. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing MRNA degradation
42. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte sub-populations of marmoset blood
43. Thalidomide is an inhibitor of angiogenesis
44. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
45. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures
46. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative
47. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
48. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
49. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
50. Inhibition of IL-12 production by thalidomide
51. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
52. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
53. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
54. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs
55. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment
56. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
57. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro
58. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: Comparisons with dexamethasone
59. Combination therapy with thalidomide and sulindac inhibits tumour growth in rabbits
60. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus
61. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects
62. Angiogenesis in cancer, vascular, rheumatoid, and other disease
63. Bone marrow angiogenesis and progression in multiple myeloma
64. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes
65. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
66. Thalidomide in GVHD is anti-GVHD effect separable from the antiangiogenesis?
67. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease
68. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide
69. Thalidomide and thrombosis
70. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients
71. Thalidomide-induced neuropathy and genetic differences in drug metabolism
72. Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation
73. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
74. Thalidomide-induced toxic epidermal necrolysis